Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis
BJR Buckley, DA Lane, P Calvert, J Zhang… - Journal of clinical …, 2022 - mdpi.com
Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …
Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management
AM Fawzy, WY Yang, GYH Lip - Expert Opinion on Drug Safety, 2019 - Taylor & Francis
ABSTRACT Introduction: Direct oral anticoagulants (DOACs) may be regarded as some of
the most successful innovations in recent times. These drugs which were specifically …
the most successful innovations in recent times. These drugs which were specifically …
Cost-effectiveness of direct non-vitamin K oral anticoagulants versus vitamin K antagonists for the management of patients with non-valvular atrial fibrillation based on …
V Lorenzoni, S Pirri, G Turchetti - Clinical drug investigation, 2021 - Springer
Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world …
SV Ramagopalan, A Sicras-Mainar… - Journal of …, 2019 - becarispublishing.com
Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …
Different risk profiles of European patients using direct oral anticoagulants or vitamin K antagonists: a rapid review
K Krueger, K Jobski, A Voss, U Haug - Current Epidemiology Reports, 2020 - Springer
Abstract Purpose of Review We investigated the risk profiles of patients using direct oral
anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to …
anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to …